Find Academic Supervisors

Daniel FinleyView profile

Professor

• Ubiquitin-Proteasome Pathway
• Proteostasis
• Protein Degradation
• +7 more

Daniel Finley is a Professor of Cell Biology at Harvard Medical School (HMS), leading the Finley Lab focused on the ubiquitin-proteasome pathway and related regulatory mechanisms. He holds academic appointments within the Department of Cell Biology and sits on the Scientific Advisory Boards of Proteostasis and X-Chem Pharmaceuticals. His research investigates proteasome function, ubiquitin-like proteins, and proteostasis roles in diseases like Alzheimer’s and ALS. Dr. Finley earned his undergraduate degree in biochemistry from Harvard University and a Ph.D. in molecular biology from MIT. After postdoctoral training at MIT, he joined HMS in 1988. His lab explores topics including erythroid proteome remodeling, mitochondrial dysfunction, and neurodegenerative disease mechanisms. Key research areas include: (1) Ubiquitin-proteasome pathway regulation, (2) Proteasome structure/function, (3) Nonproteolytic roles of ubiquitination, and (4) Pathophysiological roles of proteostasis defects in diseases. His work bridges basic cell biology with translational medicine, particularly in neurodegeneration and anemia. Finley has secured NIH funding for projects like 'Regulation of Proteasome Activity' (R35GM145246) and 'Erythrocyte maturation through global proteome remodeling' (R01HL153970). Collaborations with industry and academic partners extend his impact in drug discovery and proteasome-targeted therapies. His lab’s contributions include defining ubiquitin chain editing mechanisms, identifying USP14’s role in mitophagy, and elucidating proteostasis defects in Alzheimer's models. Research tools developed include advanced cryo-EM analyses of proteasomal structures and functional assays for ubiquitin system enzymes.

Waldemar KolanusView profile

Professor

• Molecular Immunology
• Cell Signaling
• Signal Transduction Pathways
• +4 more

Prof. Waldemar Kolanus leads the Molecular Immunology and Cell Biology department at the University of Bonn's Life & Medical Sciences Institute (LIMES) . His research bridges immunoregulation , stem cell dynamics , and metabolic stress responses in immune cells. Unit 2 member at LIMES Principal investigator in SFB 704 and ImmunoSensation Cluster Leads a multidisciplinary lab with postdocs, PhD students, and technical staff His work focuses on intracellular signaling pathways connecting immune activation to tissue homeostasis, particularly through: Cytohesin proteins in integrin-mediated adhesion and migration TRIM71 in stem cell regulation and congenital hydrocephalus High-salt environments affecting macrophage function Publication trends show expertise in immune cell migration , genetic models , and chemical inhibition , with frequent use of mice and zebrafish for in vivo studies. Key articles explore: TRIM71's dual role in auditory development and germ cell maintenance Cytohesin family's Golgi regulation and insulin signaling Ruxolitinib's off-target migration inhibition of dendritic cells Contact details: Address: LIMES Institute, Carl-Troll-Straße 31, Bonn Email: kolanus.sekretariat@uni-bonn.de Phone: +49 228 73-62788

Jennifer L ClarkeView profile

Professor

• Statistical Methodology
• Bioinformatics/Computational Biology
• Data Mining/Machine Learning
• +3 more

Jennifer L. Clarke is a Professor in the Department of Statistics at the University of Nebraska–Lincoln and Director of the Quantitative Life Science Initiative. She holds leadership roles in enabling big data integration across the University of Nebraska system through collaborative research programs. Her affiliations include the Institute of Agriculture and Natural Resources (IANR) and the College of Agriculture and Natural Resources. Dr. Clarke's research focuses on statistical methodology for high-dimensional data, computational biology, bioinformatics, and bacterial genomics. Her work bridges statistical innovation with applications in oncology, microbiome analysis, and agricultural phenomics. Key areas include predictive modeling, machine learning, and genomic/metagenomic data integration. Her recent publications span cancer biomarker discovery, plant phenotyping methodologies, and microbial community analysis, reflecting her interdisciplinary approach. Articles emphasize translational applications like therapeutic target identification and precision agriculture. Dr. Clarke leads initiatives fostering collaboration between statisticians and domain scientists, including the Quantitative Life Science Initiative and contributions to the Agricultural Genome-to-Phenome Initiative (AG2PI). Her work advances data-driven solutions for healthcare and food security challenges. Notable projects include developing statistical tools for microbiome studies, analyzing root architecture via 3D imaging, and investigating cranberry-derived compounds' cancer-inhibitory mechanisms. Her methodological contributions include hybrid clustering techniques and predictive model validation frameworks.

• DNA Repair
• Mitochondrial Biology
• Aging
• +5 more

Vilhelm Bohr is an Affiliate Professor at the Department of Cellular and Molecular Medicine , University of Copenhagen, affiliated with the Molecular Aging Program and Center for Healthy Aging . His research explores the interplay between DNA maintenance , mitochondrial biology , and aging , particularly in age-associated neurodegeneration and Alzheimer’s disease. Research Interests include: Molecular mechanisms linking NAD + metabolism to mitochondrial dysfunction and neurodegeneration Role of tau pathology in DNA damage and mitochondrial stress Impact of Aprataxin (APTX) and RECQL4 helicase defects on mitochondrial DNA integrity Pharmacological strategies to improve mitochondrial health via autophagy modulation Publications (2025-2024) span topics like NAD + biosynthesis, Werner/Rothmund-Thomson syndromes, tau nuclear functions, and mitochondrial turnover, with high citations and media attention. Collaborations extend to clinical tumor samples and CRISPR-based disease models.

• Medical Genetics
• Nephrology
• Genomics
• +3 more

Dr. Ian Wilson is a researcher at Newcastle University with a focus on medical genetics, nephrology, and genomic analysis. His work spans genetic determinants of kidney diseases, mitochondrial disorders, and biomarker development. Notable contributions include studies on uromodulin genetics in African populations, copy-number variations in rare diseases, and kidney ciliopathies. He has collaborated extensively on projects involving genome sequencing, mitochondrial replacement therapy, and muscular dystrophy biomarkers. Wilson's research integrates computational tools like machine learning for predictive modeling in urolithiasis and employs advanced imaging techniques for disease progression monitoring. Key areas: Genetic epidemiology, renal genomics, mitochondrial DNA analysis Focus on translational applications: Biomarker development for kidney stones and muscular dystrophies Interdisciplinary collaborations in ophthalmology and orthopedics His publications reflect a commitment to advancing diagnostic accuracy and understanding complex genetic disorders through multi-omics approaches.

Joshua D. RabinowitzView profile

Professor

• Cellular Metabolism
• Metabolomics
• Systems Biology
• +5 more

Joshua D. Rabinowitz is a Professor of Chemistry and the Lewis-Sigler Institute for Integrative Genomics at Princeton University, where he also serves as Director of the Ludwig Princeton Branch. His research focuses on achieving a quantitative, comprehensive understanding of cellular metabolism, with applications in both basic science and medical research. Dr. Rabinowitz's research interests span multiple areas of metabolism and systems biology: Quantitative analysis of metabolic networks and regulation Metabolomics and measurement of metabolite concentrations and fluxes Cancer cell metabolism and therapeutic targeting Metabolic regulation in microbes (E. coli, Saccharomyces cerevisiae) Biofuel production (focusing on Clostridium acetobutylicum) Metabolic impact of pathogen infection (viral infection of human cells) His laboratory has developed innovative methods for measuring cellular metabolites using state-of-the-art mass spectrometry technology and approaches for quantitating metabolic fluxes through isotope-labeling data interpretation. Analysis of recent publications reveals a strong focus on NAD+ metabolism, cancer metabolism, metabolic adaptations in disease states, and the intersection of metabolism with immunology and neuroscience, particularly in areas like T cell metabolism, Alzheimer's disease, and cardiac function. Dr. Rabinowitz has received recognition as a Highly Cited Researcher by Web of Science, indicating significant impact in his field. He advises several graduate students and has mentored numerous alumni, including Michel I. Nofal, Edmundo Leiva III, and Sean Hackett. His research is supported by multiple programs including NIH NHGRI Training Program and QCB Graduate Program. The Rabinowitz Lab operates at the intersection of chemistry, biology, and computational science, with all projects involving a mix of biological experiments, metabolomics, and computation to achieve their goal of a holistic understanding of cellular metabolism.

• Skeletal Muscle Growth
• Ribosome Biogenesis
• Exercise Physiology
• +4 more

Gustavo Nader, Ph.D., is a Professor of Kinesiology at The Pennsylvania State University's College of Health and Human Development, where he holds the Dorothy Foehr Huck and J. Loyd Huck Endowed Chair in Molecular, Cellular and Integrative Physiology. His research laboratory at 101 Noll Lab focuses on molecular mechanisms of skeletal muscle adaptation, employing human, animal, and cellular models to investigate ribosome biogenesis, transcriptional regulation, and muscle growth control in contexts ranging from exercise hypertrophy to cancer cachexia. Dr. Nader's research examines fundamental processes including: Ribosome biogenesis and its role in muscle growth regulation Epigenetic control of RNA Polymerase I activity Molecular pathways in mechanical overload-induced hypertrophy Tumor-induced muscle wasting mechanisms Biomimicry approaches inspired by hibernator physiology His work spans exercise physiology, cancer biology, and environmental stress responses. Analysis of his 15 most recent publications (2015-2025) reveals predominant themes in muscle hypertrophy mechanisms, cancer cachexia pathophysiology, ribosomal function analysis, and environmental stress impacts on muscle. His work consistently integrates molecular techniques with physiological models across species. Notable scientific recognitions include: Dorothy Foehr Huck and J. Loyd Huck Chair appointment (2024) Huck Institutes Leadership Fellowship (2025-2026) Dr. Nader leads an active research team investigating muscle plasticity, with current projects funded through the Huck Institutes of the Life Sciences. He collaborates extensively through Penn State's Integrative and Biomedical Physiology graduate program and Center for Cellular Dynamics.

Ilse DewachterView profile

Professor

• Alzheimer's Disease
• Neurodegenerative Diseases
• Therapeutic Development
• +6 more

Prof. Ilse Dewachter is the head of the Biomed Neuroscience research group at Hasselt University (UHasselt), specializing in Alzheimer’s therapy and prevention for over 25 years. Her work focuses on multi-targeted therapies targeting tau, inflammation, and ApoE, alongside pioneering research into disease prevention via blood-based biomarkers. Recent studies explore a protective APOE3ch mutation that halted Alzheimer’s progression in a patient, offering hope for new treatments. Research Interests: - Alzheimer’s disease mechanisms (Abeta, tau, inflammation) - Multi-target therapies and biomarker development - Neurodegenerative disease prevention strategies - Genetic mutations impacting disease progression Articles Overview: Her most recent work (2025-2022) addresses neuroinflammation, tau propagation models, and AI-driven neuroimaging. Key themes include APOE genetics, blood-brain barrier dynamics, and exercise impacts on cognition. Funding & Grants: Current projects require significant investment for advanced biomarker equipment and clinical trials. A notable €300,000 grant funded research on brain lipid metabolism’s role in Alzheimer’s. Labs & Teams: Leads the BIOMED Neuroscience group at UHasselt, collaborating internationally on preclinical models and drug development.

Miriam DiamondView profile

Professor

• Environmental Chemistry
• Pollution & Air Quality
• Chemical Contaminants
• +6 more

Miriam Diamond is a Professor at the Department of Earth Sciences and School of the Environment, University of Toronto. She holds cross-appointments in Chemical Engineering, Dalla Lana School of Public Health, and Physical & Environmental Sciences. PhD in Chemical Engineering (University of Toronto, 1990) MSc in Mining Engineering (Queen’s University, 1984) MSc in Zoology (University of Alberta, 1980) Her research focuses on chemical contaminant fate, transport, and exposure in indoor and urban environments, Arctic regions, and Great Lakes systems. She develops mathematical models , passive sampling methods , and policy frameworks to address pollution from flame retardants, phthalates, PFAS, and microplastics. Recent publications highlight microplastic extraction techniques , sleeping children’s exposure , and polymeric flame retardant risks . Key awards include the Royal Society of Canada Fellowship and 2025 President’s Impact Award . She supervises PhD candidates Anna Shalin , Lin Boynton , and others. Her policy contributions include serving on the Canadian Chemical Management Plan Science Committee and co-chairing the Earth Commissioner initiative.

• Neurodegenerative Diseases
• Molecular Neuroscience
• Stem Cell Research
• +3 more

Professor Richard Wade-Martins is a leading academic in University of Oxford 's Department of Physiology, Anatomy and Genetics . He directs the Molecular Neurodegeneration Research Laboratory and the Oxford Parkinson’s Disease Centre (OPDC). With degrees from Cambridge (MA) and Oxford (DPhil), he has held prestigious fellowships including Wellcome Trust Research Career Development Fellowship and NIH reviewer roles. His research targets molecular mechanisms in Parkinson’s and Alzheimer’s diseases through iPSC models , transgenic mice , and lysosomal function studies . He pioneered work on SNCA , MAPT , and LRRK2 gene pathways. Current projects focus on gene therapy and mitochondrial dysfunction in neurodegeneration. Key publications (2019–2025) reveal trends in single-cell transcriptomics , calcium channel inhibition , and TFEB/TFE3 lysosome modulation . His awards include Wellcome Trust Fellowships and advisory roles for Parkinson's UK , Alzheimer's Research UK , and EU consortia like StemBANCC and EFACTS . He leads the UK Dementia Platform iPSC Initiative and serves on international boards in Luxembourg and Canada.

• Neurobiology
• Synaptic Plasticity
• Molecular Genetics
• +7 more

Prof. Stephan J. Sigrist is a Full Professor of Genetics at the Institute of Biology, Free University of Berlin. His lab focuses on synaptic active zone architecture, neuroplasticity, and aging-related neurodegeneration. He leads the Collaborative Research Center 958 on Membrane Scaffolding and co-directs NeuroCure, a DFG Cluster of Excellence at Charité. Education: PhD in Molecular Genetics (1997) and Habilitation (2005) from the University of Göttingen. Positions: Einstein Professor (2014–present), Spokesperson CRC 958 (2012–present), and Co-Director NeuroCure (2009–present). Research explores presynaptic mechanisms using Drosophila and mouse models, combined with STED microscopy. Key contributions include discoveries of Bruchpilot's role in active zones and spermidine's protective effects against age-related synapse decline. Grants: Over €6 million in funding, including DFG CRCs, Einstein Foundation, and ERC Advanced Grant (2025). Awards: Einstein Professorship, Best Habilitation Award, EMBO/HFSP Fellowships. Collaborations span structural biology (e.g., Stefan Hell), neurophysiology (David DiGregorio), and aging research (Frank Madeo).

Martin JastrochView profile

Professor

• Energy Metabolism
• Obesity Research
• Adipose Tissue Biology
• +4 more

Martin Jastroch is a Professor at Stockholm University's Department of Molecular Biosciences, The Wenner-Gren Institute. His research focuses on the physiology and molecular mechanisms of energy metabolism from organism to molecule level. His primary research interests include: Energy metabolism physiology and molecular mechanisms Obesity and metabolic aspects Adipose tissue biology Mitochondrial mechanisms Thermogenesis and brown fat function Metabolic regulation in health and disease Professor Jastroch's research spans multiple disciplines, connecting molecular mechanisms with whole-organism physiology. His work on mitochondrial bioenergetics and thermogenesis has contributed significantly to understanding how energy metabolism is regulated across different biological scales. Recent publications show a growing interest in the evolutionary aspects of thermogenesis and the role of brown adipose tissue in metabolic diseases, with particular focus on UCP1 function, mitochondrial adaptations, and metabolic reprogramming in disease states. His scientific contributions include important findings on: UCP1 (Uncoupling Protein 1) function and regulation Mitochondrial bioenergetics in different tissue types Evolutionary aspects of mammalian thermogenesis Metabolic regulation in obesity and related disorders Links between mitochondrial dysfunction and neurodegenerative diseases Professor Jastroch leads 'Group Jastroch' at Stockholm University, where his team investigates the complex interplay between cellular energy metabolism and whole-body physiology, with implications for understanding and treating metabolic disorders.

Brent FogelView profile

Professor

• Neurogenetics
• Hereditary Ataxia
• Spinocerebellar Ataxia
• +7 more

Dr. Brent Fogel is a Professor in the Departments of Neurology and Human Genetics at the David Geffen School of Medicine, UCLA. He directs the Neurogenetics Clinic and the UCLA Clinical Neurogenomics Research Center , focusing on diagnosing and managing genetic neurological disorders such as cerebellar ataxia , ataxia with oculomotor apraxia , spastic paraplegia , and leukodystrophies . His research integrates genomics , bioinformatics , and neuroimaging to improve precision medicine in prenatal counseling and rare disease diagnosis. Education: MD, PhD from Medical College of Wisconsin (2003) PhD in Genetics (2001) Internship in Internal Medicine (Northwestern University, 2004) Residency in Neurology (UCLA, 2007) Fellowship in Neurogenetics (UCLA, 2009) Board Certified in Neurology (2009) Research Focus: Dr. Fogel’s work spans neurogenetics , spinocerebellar ataxia , leukodystrophy , and genomic technologies . He has pioneered gene discovery in hereditary ataxias, developed transcriptional biomarkers , and contributed to diagnostic guidelines for rare disorders. His studies on lysosomal genes in Parkinson’s disease and exome sequencing disparities address critical gaps in neurogenetic research. Key Collaborations: He leads multicenter studies with the Ataxia Global Initiative , Undiagnosed Diseases Network , and Genomics England Research Consortium . His lab ( FogelLab ) develops tools like multiWGCNA for gene network analysis.

• Cardiovascular Physiology
• Exercise Physiology
• Vascular Function
• +4 more

Joe Stock is an Assistant Professor in Kinesiology at East Carolina University's College of Health and Human Performance. He operates the Human Performance Lab, focusing on cardiovascular wellness in aging and at-risk populations. B.S. in Exercise Science, Slippery Rock University M.S. in Health, Physical Activity and Chronic Disease, University of Pittsburgh Ph.D. in Kinesiology and Applied Physiology, University of Delaware His research examines aortic hemodynamics, vascular function, and lifestyle interventions through echocardiography, blood vessel ultrasound, and non-invasive blood pressure analysis. He explores sex differences in neurocardiovascular responses and salt sensitivity mechanisms. Recent publications demonstrate expertise in chronic kidney disease adaptations, exercise-induced vascular changes, and central sodium sensing. Collaborations span cardiovascular physiology, nephrology, and autonomic neuroscience. National Heart, Lung, and Blood Institute grant (2021-2023) University of Delaware Dissertation Fellowship (2019) University of Delaware Summer Doctoral Fellowship (2018) Professional service includes American Heart Association membership, ACSM regional committee work, and development of clinical exercise programs for renal patients. His work integrates applied physiology with translational medicine.

Arpan MehtaView profile

Researcher

• Neurodegenerative Diseases
• Amyotrophic Lateral Sclerosis (ALS)
• Molecular Neuroscience
• +3 more

Dr. Arpan Mehta is an Independent Investigator at the MRC Protein Phosphorylation and Ubiquitylation Unit, specializing in neurodegenerative diseases with a focus on Amyotrophic Lateral Sclerosis (ALS) and frontotemporal dementia. He was awarded the 51st Sir John Halliday Croom Medal and Lectureship by the Royal College of Physicians of Edinburgh for his groundbreaking research on ALS mechanisms. His work explores the role of kinases and genetic mutations (e.g., C9ORF72) in neurodegeneration, alongside mitochondrial dysfunction and clinical trial methodologies. Research interests include molecular mechanisms underlying ALS, neuroimmunology, and improving clinical trial designs for neurodegenerative diseases. Dr. Mehta advocates for rigorous research standards, addressing reproducibility challenges, and optimizing therapeutic approaches. His recent studies investigate mitochondrial bioenergetic deficits in ALS motor neurons and the impact of cerebrospinal fluid (CSF) toxicity. Awards: Sir John Halliday Croom Medal and Lectureship (2025) His publications span clinical neurology, neurodegenerative disease mechanisms, and ethical aspects of medical practice. Dr. Mehta emphasizes interdisciplinary collaboration to advance understanding of ALS pathogenesis and translational therapies.